WO2021090910A1 - Agent d'altération de la structure moléculaire pour la détection d'agrégats protéiques, procédé de détection associé, agent de nettoyage d'équipement médical, agent de nettoyage du sol et procédé de nettoyage du sol - Google Patents

Agent d'altération de la structure moléculaire pour la détection d'agrégats protéiques, procédé de détection associé, agent de nettoyage d'équipement médical, agent de nettoyage du sol et procédé de nettoyage du sol Download PDF

Info

Publication number
WO2021090910A1
WO2021090910A1 PCT/JP2020/041521 JP2020041521W WO2021090910A1 WO 2021090910 A1 WO2021090910 A1 WO 2021090910A1 JP 2020041521 W JP2020041521 W JP 2020041521W WO 2021090910 A1 WO2021090910 A1 WO 2021090910A1
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
cleaning
disease
fluoroalcohol
mass
Prior art date
Application number
PCT/JP2020/041521
Other languages
English (en)
Japanese (ja)
Inventor
毅 小川
Original Assignee
セントラル硝子株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントラル硝子株式会社 filed Critical セントラル硝子株式会社
Publication of WO2021090910A1 publication Critical patent/WO2021090910A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/34—Halogenated alcohols
    • C07C31/38—Halogenated alcohols containing only fluorine as halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/16—Saturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the present invention relates to a molecular structure altering agent for detecting a protein that can be a pathogen of a disease group caused by a change in the higher-order structure of a protein such as prion disease, and a method for detecting the same.
  • the present invention further relates to a molecular structure altering agent and a detection method for detecting a protein having a normal three-dimensional structure and a protein having an abnormal three-dimensional structure that can be a pathogen of a disease by a difference in sensitivity.
  • the present invention relates to a cleaning agent for medical devices and a method for cleaning medical devices.
  • the present invention relates to a soil cleaning agent and a method for cleaning soil.
  • Protein becomes a molecule that functions only when it forms the correct three-dimensional structure. However, if the correct three-dimensional structure is not formed, the protein causes fibrosis and aggregation to lose its original function or acquire new toxicity, thereby inhibiting various metabolic pathways in the living body. , Eventually can be fatal. These diseases are called protein misfolding diseases, and in the area of neurological diseases, prion disease, Alzheimer's disease, Parkinson's disease, Levy body dementia and the like are included. Cataracts, age-related macula, etc. are included in the field of ophthalmology. Amyloidosis is included in systemic organs.
  • Prion protein is considered to be a pathogen that causes prion disease, which is a neurodegenerative disease.
  • Prion's disease is a common veterinary infectious disease, with sporadic Creutzfeldt-Jakob disease (CJD), hereditary Gerstmann-Sträsler-Scheinker syndrome (GSS) and fatal familial insomnia (FFI) in humans. ), Infectious variant CJD (vCJD).
  • Bovine spongiform encephalopathy BSE
  • CWD deer chronic wasting disease
  • Prion disease also develops in cats, minks, and cheetahs.
  • Non-Patent Document 1 Protein conformational changes to normal type prion protein (PrP C) from the abnormality-type prion protein (PrP Sc), rather than immediately not cause prion infection, although there is debate still for these correlations, the development of prion disease It has been clarified that PrP Sc is involved in. However, no radical cure has been found to date. (Non-Patent Document 1, Non-Patent Document 2)
  • Protein misfolding disease has already been found to have fibrosis and aggregation formation derived from proteins with abnormal three-dimensional structure in the living body long before the first clinical symptoms appear.
  • the current diagnostic criteria are, for example, sporadic prion disease, 1) showing progressive clinical symptoms, 2) showing cerebral atrophy on MRI imaging, and 3) 14- in cerebrospinal fluid. Criteria such as an increase in 3-3 protein and total tau protein are useful, but these diagnostic criteria are insufficient for early diagnosis, and further diagnostic methods are required.
  • a biopsy method that can eliminate individuals suffering from prion disease before sending them to a slaughterhouse is desired from the viewpoint of ensuring food safety.
  • the producer either senses the animal's anomaly or is found in a pre-slaughter test.
  • it may be detected by surveillance of health and cattle.
  • there are several antibodies that detect PrP Sc all of them can only be used for definitive diagnosis after death.
  • PrP Sc In prion disease, it is often considered that PrP Sc accumulates as protein aggregates inside and outside nerve cells in the brain and exhibits pathogenicity, especially in the central nervous system in the living body. PrP Sc is has exactly the same amino acid sequence as PrP C, the three-dimensional structure of the protein are very different, PrP C is contains many ⁇ - helical structure, the PrP Sc contains many ⁇ - sheet structure It has been. Therefore, PrP Sc becomes a poorly soluble and poorly degradable protein and exhibits resistance to degradation by proteolytic enzymes such as proteinase K. Conformational conversion mechanism from PrP C to PrP Sc is not yet clear. In addition, it is said that changes in the three-dimensional structure have neurotoxicity and destroy nerve cells and the like over time, but the details are still unknown. Alzheimer's disease, Parkinson's disease, Levy body dementia, etc. are also caused by amyloid ⁇ protein, tau protein, ⁇ -synuclein, etc. as protein aggregates, respectively. Is believed to be caused by.
  • the central nervous system is composed of a group of cells that have completed differentiation, so once a group of proteins with three-dimensional structural abnormalities accumulates, they are not metabolized and remain in nerve cells.
  • Patent Document 1 discloses a measurement method capable of detecting a 14-3-3 protein ⁇ isoform in a biological sample with high sensitivity by an ELISA method (enzyme-linked immunosorbent assay) instead of the conventional Western blotting method. There is.
  • the 14-3-3 protein ⁇ isoform is a marker capable of detecting rapid nerve destruction in prion disease, and is known to be detected in cerebrospinal fluid in progressive neuropathy.
  • Patent Document 2 discloses a compound labeled with a radionuclide as a diagnostic imaging probe for prion protein-accumulating diseases. This allows imaging of prion proteins using positron emission tomography (PET).
  • PET positron emission tomography
  • the problem with PET is that there are restrictions on the inspection sensitivity and the inspection time. Considering the half-life of the compound labeled with the radionuclide, the labeled compound must be synthesized by an automatic synthesizer immediately before the test.
  • Patent Document 3 discloses an RNA aptamer, which is a nucleic acid molecule that binds to an abnormal prion-derived fibril.
  • RNA aptamers bound to fibrils can be detected by PET or a fluorescence detector if they are labeled in advance, and even if they are not labeled, they can be detected by a crystal oscillator or a surface plasmon resonance detector.
  • One embodiment of the present invention has been made in view of the above, and an object of the present invention is to provide a molecular structure altering agent capable of specifically interacting with a protein aggregate and detecting it, and a method for detecting the same. ..
  • one embodiment of the present invention aims to provide a cleaning agent for cleaning a medical device contaminated with protein aggregates and a method for cleaning the medical device.
  • one embodiment of the present invention aims to provide a cleaning agent for cleaning soil contaminated with protein aggregates and a method for cleaning soil.
  • HFIP fluoroalcohol 1,1,1,3,3,3-hexafluoro-2-propanol
  • the present invention includes the following aspects.
  • a 0 or 1
  • R 1 is a hydrogen atom and R 2 is a hydroxyl group, or R 1 is a hydroxyl group and R 2 is a hydrogen atom.
  • R 2 is an oxygen atom that forms a double bond with the carbon atom.
  • R 3 is CH l Cl m F n
  • l is an integer from 0 to 3
  • R 4 is CH s Cl t F u
  • s is an integer from 0 to 3
  • Fluoro-based alcohols are represented by the general formula RfCH 2 OH or RfRf'CHOH, Rf and Rf'represent a perfluoroalkyl group having 1 to 10 carbon atoms, and Rf and Rf'are different or the same.
  • a molecular structure altering agent is represented by the general formula RfCH 2 OH or RfRf'CHOH, Rf and Rf'represent a perfluoroalkyl group having 1 to 10 carbon atoms, and Rf and Rf'are different or the same.
  • a molecular structure altering agent in which the fluoroalcohol is 1,1,1,3,3,3-hexafluoro-2-propanol.
  • a molecular structure altering agent in which the concentration of a fluoroalcohol or a compound represented by the general formula (1) when acting on a protein aggregate is in the range of 10 pM to 100 mM.
  • [5] A molecular structure altering agent used for diagnosing protein misfolding disease.
  • Protein misfolding disease includes sporadic Creutzfeldt-Jakob disease (CJD) in humans, hereditary Gerstmann-Sträsler-Scheinker syndrome (GSS), lethal familial insomnia (FFI), and medical doctors.
  • CJD Creutzfeldt-Jakob disease
  • GSS hereditary Gerstmann-Sträsler-Scheinker syndrome
  • FFI lethal familial insomnia
  • a prion disease in animals that can develop prion disease such as primary and dietary variants CJD (vCJD), bovine spongiform encephalopathy (BSE), sheep scrapy, deer chronic wasting disease (CWD), cats, minks, and cheetahs.
  • vCJD primary and dietary variants CJD
  • BSE bovine spongiform encephalopathy
  • CWD deer chronic wasting disease
  • cats minks, and cheetahs.
  • FTLD frontotemporal lobar degeneration
  • FTLD muscle atrophic lateral sclerosis
  • Huntington chorea polyglutamine disease
  • cataracts aging
  • a method for detecting protein aggregates which comprises allowing a fluoroalcohol or a compound represented by the following general formula (1) to act on the protein aggregates.
  • a 0 or 1
  • R 1 is a hydrogen atom and R 2 is a hydroxyl group, or R 1 is a hydroxyl group and R 2 is a hydrogen atom.
  • R 2 is an oxygen atom that forms a double bond with the carbon atom.
  • R 3 is CH l Cl m F n
  • l is an integer from 0 to 3
  • R 4 is CH s Cl t F u
  • s is an integer from 0 to 3
  • Fluoro-based alcohols are represented by the general formula RfCH 2 OH or RfRf'CHOH, Rf and Rf'represent a perfluoroalkyl group having 1 to 10 carbon atoms, and Rf and Rf' are different or the same as each other. Method for detecting protein aggregates.
  • a method for detecting protein aggregates in which the concentration of a fluoroalcohol or a compound represented by the general formula (1) when acting on protein aggregates is in the range of 10 pM to 100 mM.
  • [11] A method for detecting protein aggregates used for diagnosing protein misfolding disease.
  • Protein misfolding disease includes sporadic Creutzfeldt-Jakob disease (CJD) in humans, hereditary Gerstmann-Sträsler-Scheinker syndrome (GSS), lethal familial insomnia (FFI), and medical doctors.
  • Alzheimer, a prion disease in animals that can develop prion disease such as primary and dietary mutant CJD (vCJD), bovine spongiform encephalopathy (BSE), sheep scrapy, deer chronic wasting disease (CWD), cats, minks, and cheetah Diseases, Parkinson's disease, Levy body dementia, neurodegenerative diseases included in the spectrum of frontotemporal lobar degeneration (FTLD), muscle atrophic lateral sclerosis, Huntington chorea, polyglutamine disease, cataracts, aging
  • FTLD frontotemporal lobar degeneration
  • FTLD muscle atrophic lateral sclerosis
  • Huntington chorea polyglutamine disease
  • cataracts cataracts
  • a method for detecting protein aggregates which is one disease selected from the group consisting of sex yellow spot and systemic amyloidosis.
  • a 0 or 1
  • R 1 is a hydrogen atom and R 2 is a hydroxyl group, or R 1 is a hydroxyl group and R 2 is a hydrogen atom.
  • R 2 is an oxygen atom that forms a double bond with the carbon atom.
  • R 3 is CH l Cl m F n
  • l is an integer from 0 to 3
  • R 4 is CH s Cl t F u
  • s is an integer from 0 to 3
  • the fluoroalcohol of the test kit is represented by the general formula RfCH 2 OH or RfR f'CHOH.
  • Rf and Rf' represent a perfluoroalkyl group having 1 to 10 carbon atoms.
  • Rf and Rf' are different or the same as each other.
  • the fluorine-based alcohol in the test kit is 1,1,1,3,3,3-hexafluoro-2-propanol.
  • the concentration of the fluoroalcohol or the compound represented by the general formula (1) when acting on the protein aggregate of the test kit is in the range of 10 pM to 100 mM.
  • An inspection device for detecting protein aggregates which comprises a detection unit containing a fluoroalcohol or a compound represented by the following general formula (1) as a compound for detecting protein aggregates.
  • a 0 or 1
  • R 1 is a hydrogen atom and R 2 is a hydroxyl group, or R 1 is a hydroxyl group and R 2 is a hydrogen atom.
  • R 2 is an oxygen atom that forms a double bond with the carbon atom.
  • R 3 is CH l Cl m F n
  • l is an integer from 0 to 3
  • R 4 is CH s Cl t F u
  • s is an integer from 0 to 3
  • the fluorinated alcohol of the inspection device is represented by the general formula RfCH 2 OH or RfR f'CHOH.
  • Rf and Rf' represent a perfluoroalkyl group having 1 to 10 carbon atoms.
  • Rf and Rf' are different or the same as each other.
  • the fluoroalcohol of the inspection device is 1,1,1,3,3,3-hexafluoro-2-propanol.
  • the concentration of the fluorinated alcohol or the compound represented by the general formula (1) when acting on the protein aggregate of the inspection device is in the range of 10 pM to 100 mM.
  • a cleaning agent for medical instruments containing a fluorinated alcohol or a compound represented by the following general formula (1) a is 0 or 1
  • R 1 is a hydrogen atom and R 2 is a hydroxyl group, or R 1 is a hydroxyl group and R 2 is a hydrogen atom.
  • R 2 is an oxygen atom that forms a double bond with the carbon atom.
  • R 3 is CH l Cl m F n
  • l is an integer from 0 to 3
  • R 4 is CH s Cl t F u
  • s is an integer from 0 to 3
  • the fluoroalcohol is represented by the general formula RfCH 2 OH or RfRf'CHOH, and Rf and Rf'represent a perfluoroalkyl group having 1 to 10 carbon atoms. Rf'is different or the same as each other.
  • the fluoroalcohol is 1,1,1,3,3,3-hexafluoro-2-propanol.
  • R 3 is CH l Cl m F n
  • l is an integer from 0 to 3
  • R 4 is CH s Cl t F u
  • s is an integer from 0 to 3
  • the fluoroalcohol is represented by the general formula RfCH 2 OH or RfRf'CHOH, Rf and Rf'represent a perfluoroalkyl group having 1 to 10 carbon atoms, and Rf and Rf' Are different or the same as each other.
  • the fluoroalcohol is 1,1,1,3,3,3-hexafluoro-2-propanol.
  • a molecular structure altering agent that alters a protein three-dimensional structure with respect to protein aggregates accumulated in humans and animals is provided, protein aggregates are detected, and protein misfolding disease is diagnosed.
  • FIG. 1 It is a schematic diagram which shows the cleaning apparatus 1 which concerns on one Embodiment of this invention.
  • a photograph of Neuro 2a (N2a) cells and ScNeuro 2a (ScN2a) cell culture plate was tested sensitivity at each concentration of HFIP for cells producing PrP Sc producing a PrP C is there.
  • the compound that alters the molecular structure of human and animal protein aggregates of the present invention is a fluoroalcohol or a compound represented by the following general formula (1).
  • R 1 is a hydrogen atom and R 2 is a hydroxyl group.
  • R 1 is a hydroxyl group and R 2 is a hydrogen atom.
  • R 3 is CH l Cl m F n
  • l is an integer from 0 to 3
  • the molecular structure altering agent contains a fluorinated alcohol or a compound represented by the above general formula as an active ingredient.
  • the "molecular structure modifier” specifically acts on a protein containing a large amount of ⁇ -sheet structure to unfold the molecular structure from the ⁇ -sheet structure to form an ⁇ -helix structure. It contains an inducing compound and can be suitably used for detection of protein aggregates and simple screening and diagnosis of protein misfolding diseases including neurodegenerative diseases.
  • the molecular structure altering agent contains two or more selected from a fluoroalcohol and a compound represented by the above general formula.
  • the compound represented by the general formula (1) may be selected from the compound group represented by the following compounds 1 to 3. [Compound group]
  • the fluoroalcohol of the present invention is represented by the following general formula (2) or (3).
  • Rf and Rf' represent a perfluoroalkyl group having 1 to 10 carbon atoms.
  • HFIP 1,1,1,3,3,3-hexafluoro-2-propanol
  • 2,2. 2-Trifluoroethanol
  • 2,2,3,3,3-pentafluoro-1-propanol can be exemplified.
  • HFIP is suitable as a compound that alters the molecular structure of protein aggregates.
  • the molecular structure altering agent may contain at least one of the compounds represented by the general formulas (1), (2) or (3) and a solvent.
  • the solvent capable of diluting the compound represented by the general formula (1), (2) or (3) examples include water, physiological saline, Ringer's solution, phosphate buffered saline (PBS), methanol, and the like. Examples include, but are not limited to, ethanol, isopropanol, acetone, toluene, dimethyl sulfoxide and the like.
  • the molecular structure altering agent contains the compound represented by the general formula (1), (2) or (3) and the above solvent.
  • HFIP is a colorless and transparent liquid with a melting point of -3.3 ° C and a boiling point of 58.6 ° C, and is soluble in most solvents. Therefore, HFIP should be adjusted to an arbitrary concentration by diluting with a solvent. Can be done.
  • the concentration of the fluoroalcohol or the compound represented by the general formula (1) when acting on the protein aggregate is preferably in the range of 10 pM or more and 100 mM or less.
  • the time for allowing the fluoroalcohol or the compound represented by the general formula (1) to act on the protein aggregate is not particularly limited.
  • it is represented by a fluorinated alcohol or a compound represented by the general formula (1), or instead of the fluorinated alcohol or the compound represented by the general formula (1).
  • a compound in which the hydroxy group in the compound is protected by a protecting group may be used. This protecting group suppresses the decomposition of the fluoroalcohol or the compound represented by the general formula (1) in the process of acting on the protein aggregate, and this compound is the fluoroalcohol or the general when acting on the protein aggregate. It suffices if it is converted into the compound represented by the formula (1).
  • protecting groups include functional groups generally used as protecting groups for hydroxy groups (see, for example, "Protecting Group Chemistry” by Jeremy Robertson, published by Oxford University Press), sugar chains, peptides and the like.
  • functional group used as the protective group include acetal-based functional groups such as an alkoxyalkyl group (for example, methoxymethyl group and ethoxyethyl group) and 2-tetrahydropyranyl group, and an alkanoyl group (for example, acetyl group) and an aloyl group.
  • Acrylic functional group such as (for example, arylmethyl group such as benzyl group, benzoyl group), silyl ether functional group such as alkylsilyl group (for example, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group)
  • alkylsilyl group for example, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group
  • the present invention is not limited thereto.
  • the molecular structure altering agent containing the fluoroalcohol of the present invention or the compound represented by the general formula (1) can be used for diagnosing protein misfolding diseases, particularly neurodegenerative diseases, and at a pharmaceutically acceptable concentration. It can be contained as an active ingredient to form a test kit.
  • the pharmaceutically acceptable concentration is the same as the concentration that alters the molecular structure of the protein aggregate, and specifically, the concentration is preferably in the range of 10 pM or more and 100 mM.
  • the test kit comprises HFIP and the solvent described above.
  • protein misfolding diseases in the nervous system include sporadic Creutzfeldt-Jakob disease (CJD), hereditary Gerstmann-Sträsler-Scheinker syndrome (GSS), and lethal families in prion disease.
  • CJD chronic Creutzfeldt-Jakob disease
  • GSS hereditary Gerstmann-Sträsler-Scheinker syndrome
  • lethal families in prion disease include sexual insomnia (FFI), iatrogenic and dietary mutant CJD (vCJD), bovine spongiform encephalopathy (BSE), sheep scrapy, deer chronic wasting disease (CWD), cats, minks, cheetahs, etc.
  • FFI sexual insomnia
  • vCJD iatrogenic and dietary mutant CJD
  • BSE bovine spongiform encephalopathy
  • CeWD deer chronic wasting disease
  • cats minks, cheetahs, etc.
  • minks cheeta
  • Alzheimer's disease Parkinson's disease, Lewy body dementias, neurodegenerative diseases in the frontotemporal lobar degeneration (FTLD) spectrum, muscle atrophic lateral sclerosis, Huntington's chorea, and polyglutamine disease.
  • FTLD frontotemporal lobar degeneration
  • muscle atrophic lateral sclerosis Huntington's chorea
  • polyglutamine disease Can be exemplified.
  • cataracts, age-related macula and the like can be exemplified.
  • Amyloidosis is included in systemic organs.
  • proteins showing a normal three-dimensional structure cause higher-order structural changes in proteins with an abnormal three-dimensional structure, which accumulate inside and outside nerve cells in the brain as protein aggregates, especially in the central nervous system. It is believed to be pathogenic.
  • the amino acid sequence of a protein does not change during this process, only its conformation.
  • Normal proteins contain a large amount of ⁇ -helix structure as a secondary structure, but proteins with an abnormal three-dimensional structure contain a large amount of ⁇ -sheet structure, which makes them sparingly soluble and persistently degradable, such as proteinase K. Shows resistance to proteolytic enzymes.
  • the fluoroalcohol contained in the molecular structure altering agent of the present invention acts specifically on the ⁇ -sheet structure of a protein to unfold the molecular structure from the ⁇ -sheet structure and induce it into an ⁇ -helix structure.
  • HFIP is a low molecular weight compound having a molecular weight of 168, and has a molecular size capable of crossing the cerebral blood barrier that controls substance exchange between blood and brain tissue fluid (generally, a molecule having a molecular weight of more than 500). (It is said that it cannot pass through), and it is thought that it moves into the brain and functions as a molecular structure modifier.
  • biological samples that can be used in the method for detecting protein aggregates of the present invention include organs, biological tissues, and cells suspected of being infected with protein misfolding disease, such as the brain, spinal cord, and the like. Tonsillar, nerve junction, spleen, heart, liver, lung, eyeball, placenta, testis, lymphatic tissue, muscle tissue, etc., or nerve cells, blood cells, muscle cells, and blood (including liquid components of plasma and serum), Body fluids such as cerebrospinal fluid (medullary fluid) and urine are not particularly limited as long as protein aggregates can be detected by the method for detecting protein aggregates of the present invention. Blood, cerebrospinal fluid, and the like are preferable because they are relatively minimally invasive samples. In addition, tonsils, nerve junctions, etc. are tissues that are easier to collect than the brain, and are suitable for diagnosis of industrial animals.
  • Biological samples infected with protein misfolding disease include cells containing protein aggregates, and by utilizing the difference in susceptibility between these cells and a fluoroalcohol or a compound represented by the general formula (1), It can be used for simple screening and diagnosis of protein misfolding disease.
  • cells suffering from protein misfolding disease lead to cell death depending on the concentration of fluoroalcohol or the compound represented by the general formula (1) as compared to normal cells.
  • biological samples collected from living tissues may be used after culturing in vitro.
  • the suitable biological sample differs depending on the protein to be detected, and is not particularly limited.
  • PrP Sc is said to be present in cerebrospinal fluid, and amyloid beta such as Alzheimer's disease is also present in blood.
  • the detection of protein aggregates of the present invention can be used not only for simple screening and diagnosis of protein misfolding disease, but also for tests for preventing infection by blood for transfusion, blood products, spinal fluid, organs for transplantation, and the like.
  • blood donors have restrictions on the tests for prion infection of blood for transfusion, such as the history of overseas stays and disease history of blood donors.
  • the test for altering the molecular structure of a protein aggregate using the fluoroalcohol of the present invention or the compound represented by the general formula (1) is a method capable of evaluating a protein having a normal molecular structure and a protein having an abnormal molecular structure, respectively. If there is, there is no particular limitation.
  • protein aggregates are accumulated due to the difference in sensitivity between normal cells and cells in which protein aggregates are accumulated to the molecular structure altering agent of the present invention.
  • the presence or absence of cells can be detected.
  • the presence or absence of cells in which protein aggregates have accumulated can be detected by allowing cells to act on the molecular structure altering agent of the present invention for a predetermined time and then evaluating live cells or dead cells by cell staining.
  • the protein aggregate when the above tissue or cell is used as a biological sample, the protein aggregate is due to the difference in sensitivity of the protein having a normal structure to the molecular structure altering agent of the present invention and the protein aggregate to a proteolytic enzyme.
  • the presence or absence of accumulated tissue or cells can be detected.
  • the protein aggregate when the cell lysate is treated with a proteolytic enzyme, the protein aggregate is not decomposed by the proteolytic enzyme, and a band derived from the protein aggregate is detected by electrophoresis.
  • the protein aggregates altered by the molecular structure alteration agent are decomposed by the proteolytic enzyme, and a band of the protein aggregates is electrophoresed. Dilutes or disappears. Therefore, the presence or absence of tissues or cells in which protein aggregates have accumulated can be detected by the difference in sensitivity to proteolytic enzymes before and after treatment with the molecular structure altering agent of the present invention. Further, even when the protein on which the protein aggregation is formed is unknown, the protein can be identified by, for example, mass spectrometry by a shotgun method or a combination of two-dimensional electrophoresis and mass spectrometry. ..
  • FIG. 4 is a schematic view showing an inspection device 100 according to an embodiment of the present invention.
  • the inspection device 100 includes, but is not limited to, for example, an input unit 110, a detection unit 120, a storage unit 130, a display unit 140, a control unit 150, a calculation unit 160, a power supply device 170, and a communication unit 180. .. Further, the inspection device 100 may be connected to the server 300 via the network 200.
  • the input unit 110 is, for example, a device for inputting information such as an inspection target and inspection conditions into the inspection device 100, and may be composed of a known input device such as a keyboard, mouse, or touch panel.
  • the information to be tested may be, for example, the above-mentioned cell or tissue name, patient name, ID, or the like.
  • the test conditions may be conditions related to the test such as the name and concentration of the fluoroalcohol or the compound represented by the general formula (1), the date and time of the test, and the number of cells according to the present invention.
  • the detection unit 120 is a device for detecting the state of cells or protein aggregates by adding, for example, the fluoroalcohol according to the present invention or the compound represented by the general formula (1) to cells to be inspected.
  • the detection unit 120 may contain a fluorinated alcohol according to the present invention or a compound represented by the general formula (1).
  • the detection unit 120 supplies a fluorine-based alcohol according to the present invention or a compound represented by the general formula (1) to cells or the like placed in a container for detection to detect the state of cells or protein aggregates. You may.
  • the detection unit 120 supplies a fluoroalcohol or a compound represented by the general formula (1) according to the present invention to perform a series of processes for detecting the state of cells and protein aggregates.
  • the means of the above may be shown, and the detection unit 120 may detect the state of cells or protein aggregates by supplying the fluoroalcohol according to the present invention or the compound represented by the general formula (1) by a person.
  • the detection unit 120 may include an electrophoresis device for detecting the state of protein aggregates.
  • the detection unit 120 may be provided with an imaging device in order to detect the state of cells and protein aggregates.
  • the image pickup apparatus for example, a known CCD image sensor or CMOS image sensor can be used, and therefore detailed description thereof will be omitted.
  • the storage unit 130 includes a main storage device and an auxiliary storage device. Since a known memory can be used as the main storage device, detailed description thereof will be omitted. Further, since a known hard disk, solid state drive (SSD), or the like can be used as the auxiliary storage device, detailed description thereof will be omitted.
  • the storage unit 130 can store data such as an operating system, application software, and detection results for the inspection device 100.
  • the auxiliary storage device is not essential. For example, when the inspection device 100 is connected to the server 300 via the network 200, data such as application software and inspection results may be stored in the server 300.
  • the display unit 140 is a device for displaying information for operating the inspection device 100, inspection results, and the like, and a known display can be used, detailed description thereof will be omitted.
  • the control unit 150 is composed of a central processing unit and a program for controlling the inspection device 100.
  • the control unit 150 includes, for example, an operating system, application software, or modules.
  • the calculation unit 160 executes a calculation based on the information of the inspection target input from the input unit 110, the inspection conditions, and the state of the cells and protein aggregates acquired by the detection unit 120, and provides the inspection result.
  • the calculation unit 160 includes application software or a module used for calculation.
  • the power supply device 170 is a device for supplying power to the inspection device 100 from the outside and a known power supply device or battery can be used, detailed description thereof will be omitted.
  • the communication unit 180 is a device for the inspection device 100 to communicate with an external device by wire or wirelessly.
  • the communication unit 180 can be connected to the server 300 or another device (not shown) via a known local area network (LAN) or a network 200 such as the Internet.
  • LAN local area network
  • a network 200 such as the Internet.
  • the inspection device 100 detects the state of cells to be inspected and the state of protein aggregates after the action of the fluorinated alcohol according to the present invention or the compound represented by the general formula (1).
  • the risk of developing protein misfolding disease and the degree of progression of the pathological condition may be evaluated by detecting with the above and comparing with the control data or the standard value stored in the storage unit 130 or the server 300.
  • the inspection device 100 compares the inspection result at the time of inspection (first time point) with the previous inspection result stored in the storage unit 130 or the server 300 (second time point), and compares the protein.
  • the risk of developing misfolding disease and the degree of progression of the condition may be assessed.
  • the inspection device 100 causes the neural network to perform machine learning processing using the teacher data stored in the storage unit 130 or the server 300, and uses the trained neural network to perform the inspection detected by the detection unit 120. Based on the subject's data, the risk of developing protein misfolding disease and the degree of progression of the condition may be evaluated.
  • the teacher data includes predetermined input data (detection results, etc.) related to each sample collected from a plurality of samples, and output data indicating that the organism from which the sample was collected may have protein misfolding disease. Including.
  • the inspection device 100 may output the evaluation result by a printer via the communication unit 180, and the inspection device 100 may output the evaluation result from the communication unit 180 to the terminal 400 for an electronic medical record or a medical worker via the network 200.
  • the evaluation result may be sent.
  • the molecular structure altering agent according to the present invention described above can be used as a cleaning agent for medical instruments in one embodiment.
  • the risk of CJD infection via instruments used in neurosurgery in CJD patients has been pointed out.
  • the UK CJD Incident Panel reports that the pathogenicity of PrP Sc adhering to surgical instruments is removed by about 10 normal disinfections when normal disinfection is used. Therefore, it is difficult to sufficiently reduce the risk of CJD infection by the usual cleaning method of medical devices.
  • the cleaning agent for medical instruments contains the above-mentioned molecular structure altering agent according to the present invention, and may further contain a solvent.
  • the solvent can be selected from materials that can dilute the molecular structure altering agent, such as water, physiological saline, borate buffer, phosphate buffer (for example, phosphate buffered saline (also referred to as PBS)), acetate buffer, etc. Examples thereof include Tris buffer, HEPES buffer, methanol, ethanol, isopropanol, acetone, toluene, dimethyl sulfoxide, ethylene glycol, diethylene glycol and propylene glycol. These may be one or more, but are not limited thereto.
  • HFIP is a colorless and transparent liquid with a melting point of -3.3 ° C and a boiling point of 58.6 ° C, and is soluble in most solvents. Therefore, HFIP can be adjusted to an arbitrary concentration by diluting with a solvent. can do.
  • the content (% by mass) of the solvent contained in the cleaning agent for medical instruments is 0% by mass or more and 99.9% by mass or less with respect to the mass of the cleaning agent for medical instruments from the viewpoint of detergency. It may be 0% by mass or more and 99% by mass or less, 0% by mass or more and 92% by mass or less is particularly preferable, and 0% by mass or more and 71% by mass or less is further preferable.
  • the cleaning agent for medical instruments may contain additives in addition to the molecular structure altering agent and the solvent.
  • Additives that can be added to medical device cleaning agents include surfactants, enzymes, chelating agents, enzyme stabilizers, blood coagulation inhibitors, metal corrosion inhibitors, low molecular weight polyols, cleaning aids (builders), and defoamers. Agents, pH regulators, fragrances, colorants, antioxidants, preservatives, bleaching agents, bleaching activators, corrosion inhibitors dispersants, thickeners, viscosity regulators, etc., but are limited to these. It's not a thing.
  • the cleaning agent for medical instruments may contain one or more additives. In one embodiment, the cleaning agent for medical instruments can further improve the cleaning power by containing a molecular structure altering agent, a solvent, and the above-mentioned additive.
  • Surfactants (A) include nonionic surfactants (A-1), anionic surfactants (A-2), cationic surfactants (A-3), and amphoteric surfactants (A-). 4) and biosurfactant (A-5) are included.
  • nonionic surfactant (A-1) examples include an alkylene oxide-added nonionic surfactant (A-1-1) and a polyhydric alcohol-type nonionic surfactant (A-1-2). Can be mentioned.
  • alkylene oxide adduct nonionic surfactant As the alkylene oxide adduct nonionic surfactant (A-1-1), a higher alcohol (8 to 18 carbon atoms) alkylene (2 to 4 carbon atoms, preferably 2) oxide adduct (1 active hydrogen) Per addition mole number 1 to 30), alkyl (carbon number 1 to 12) phenol ethylene oxide (hereinafter, ethylene oxide may be referred to as EO) adduct (addition mole number 1 to 30), higher amine (carbon) Numbers 8 to 22) alkylene (2 to 4 carbon atoms, preferably 2) oxide adduct (1 to 40 moles added per active hydrogen), fatty acid (8 to 18 carbon atoms) EO adduct (active hydrogen) 1 to 60 moles added per piece), polypropylene glycol (200 to 4000 molecular weight) EO adduct (1 to 50 moles added per active hydrogen), polyoxyethylene (3 to 30 repeating units) alkyl (6 to 20 carbon atoms) Allyl
  • polyhydric alcohol-type nonionic surfactant (A-1-2) examples include polyvalent (2 to 8-valent or higher) such as glycerin monostearate, glycerin monooleate, sorbitan monolaurate and sorbitan monoolate.
  • polyvalent (2 to 8-valent or higher) such as glycerin monostearate, glycerin monooleate, sorbitan monolaurate and sorbitan monoolate.
  • examples thereof include fatty acid (8 to 24 carbon atoms) esters of alcohols (2 to 30 carbon atoms) and fatty acid alkanolamides such as lauric acid monoethanolamide and lauric acid diethanolamide.
  • Examples of the cationic surfactant (A-3) include quaternary ammonium salt type [stearyltrimethylammonium chloride, behenyltrimethylammonium chloride, distearyldimethylammonium chloride and lanolin fatty acid ethyl sulfate aminopropylethyldimethylammonium, etc.] and amine salts. Types [diethylaminoethylamide stearate, dilaurylamine hydrochloride, oleylamine, etc.] and the like can be mentioned.
  • amphoteric tenside agent (A-4) examples include betaine-type amphoteric tenside agents [coconut oil fatty acid amidopropyldimethylaminoacetic acid betaine, lauryldimethylaminoacetic acid betaine, 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazole. Nium betaine, lauryl hydroxysulfobetaine, lauroylamide ethyl hydroxyethyl carboxymethyl betaine sodium hydroxypropyl phosphate, etc.], amino acid amphoteric tenside [ ⁇ -lauryl aminopropionate, etc.] can be mentioned.
  • biosurfactant (A-5) examples include surfactin, ramnolipid, and salts thereof.
  • the salt examples include alkali metal salts, alkaline earth metal salts, onium salts and the like.
  • the surfactant (A) one type or two or more types can be used.
  • the combination includes, for example, a nonionic surfactant (A-1) and an anionic surfactant (A-2), a nonionic surfactant (A-1) and a cation.
  • examples thereof include a combination of an amphoteric surfactant (A-3), a nonionic surfactant (A-1) and an amphoteric surfactant (A-4).
  • the nonionic surfactant (A-1) can be used alone, and the nonionic surfactant (A-1) and the anionic surfactant (A-1) can be used alone. It is preferable to use it in combination with -2).
  • the anionic surfactant (A-2) includes an alkylphenyl sulfonate having 8 to 24 carbon atoms, a fatty acid salt, an alkyl sulfate ester salt having 8 to 24 carbon atoms, and an alkyl sulfate ester salt having 8 to 24 carbon atoms from the viewpoint of detergency.
  • Amine salt and sodium laurate is preferably an alkylphenyl sulfonate having 8 to 24 carbon atoms, a fatty acid salt, an alkyl sulfate ester salt having 8 to 24 carbon atoms from the viewpoint of detergency.
  • the content (mass%) of the surfactant (A) contained in the cleaning agent for medical instruments is preferably 0% by mass or more and 10% by mass or less with respect to the mass of the cleaning agent for medical instruments from the viewpoint of detergency. , More preferably 0.1% by mass or more and 5% by mass or less.
  • Enzyme (B) includes protease (B-1), amylase (B-2), lipase (B-3) and cellulase (B-4), aminopeptidase and the like.
  • the protease (B-1) is an enzyme that catalyzes hydrolysis using a peptide or protein as a substrate.
  • the protease (B-1) includes those of animal, plant or microbial origin, and those of microbial origin are preferable from the viewpoint of availability. Also included are chemically or genetically modified variants.
  • the protease (B-1) may be a protease (alkaline protease) having an optimum pH on the neutral to alkaline side, and a plurality of proteases satisfying this condition can be used in combination.
  • Examples of the protease (B-1) include serine protease (B-1-1), aspartic protease (B-1-2), cysteine protease (B-1--3) and metalloprotease (B-1--4). included.
  • Serine protease (B-1-1) is a protease having a serine residue as a catalytic residue, and is a chymotrypsin, trypsin, thrombin, plasmin, elastase, subtilisin (subtilisin E, subtilisin BPN'), kexin, and actinomycete (subtilisin E, subtilisin BPN'). It includes proteases derived from (streptomyces), proteases derived from subtilisin (Bacillus), proteases derived from filamentous fungi (Aspergillus), and the like.
  • Serine protease (B-1-1) is a protease in which a serine residue is involved in the active center, and is inactivated by a drug such as diisopropylfluorophosphoric acid or phenylmethanesulfonylfloride that specifically binds to the serine residue. It has been known. Serine protease (B-1-1) does not require a reducing agent, is not affected by a metal chelating agent, and has an optimum pH of enzyme activity near neutrality, and is therefore preferably used in this embodiment. Be done.
  • B-1-1 serine proteases
  • B-1-1 Commercially available serine proteases (B-1-1) include Alcalase, Sabinase, Evalase, Esperase, Cannase, Ovozyme, Subtilisin A, PEM, PTN, Primase, Durazym manufactured by Novozymes, and Bioplase manufactured by Nagase Biochemical Industry Co., Ltd. , Protease N "Amano” manufactured by Amano Pharmaceutical Co., Ltd., Protease P "Amano”, Actinase AS manufactured by Kaken Pharmaceutical Co., Ltd., KAP manufactured by Kao Co., Ltd. Examples thereof include pronase, TrypLE Select manufactured by Invitrogen Co., Ltd., and Accutase manufactured by Chemicon International. Further, the protease described in JP-A-2007-61101 can also be preferably used.
  • Aspartic protease (B-1-2) is a protease in which aspartic acid is present in the active center, and includes pepsin, cathepsin D, cathepsin E, renin, chymosin, and the like. Specific examples include pepsin derived from the human stomach. Aspartic protease (B-1-2) is a protease generally also called an acidic protease and has enzymatic activity in the acidic region. HFIP is suitable because it is acidic.
  • Cysteine protease (B-1--3) is a protease in which a thiol group is present in the active center, and includes papain, bromelain, ficin, actinidin, cathepsin B, cathepsin H, cathepsin L, caspase, ginger protease and the like. Since the active center of cysteine protease (B-1--3) is a thiol group, it is preferable to use a reducing agent such as cysteine or thiourea in combination. From the viewpoint of preventing oxidation by oxygen in the air, such a reducing agent is preferably added to the cleaning agent immediately before or during cleaning.
  • the metalloprotease (B-1--4) is a protease containing a metal ion in the active center, and examples thereof include thermolysin, matrix metalloproteinase, carboxypeptidase A, carboxypeptidase B, dispase, and collagenase.
  • examples of commercially available metalloproteases (B-1-4) include dispase manufactured by Worthington Biochemical Corporation.
  • a metal-free chelating agent from the viewpoint of maintaining the activity of the metalloproteinase.
  • subtilisin and plasmin are more preferable, from the viewpoint of long-lasting effect and detergency. Is. Of these, subtilisins derived from Bacillus Hallodurans and Bacillus clausii are preferable.
  • the cleaning agent for medical instruments can clean the adhered protein stains more efficiently by containing the protease (B-1).
  • the protease (B-1) may be contained in the cleaning agent for medical instruments, but the cleaning agent containing the protease (B-1) may be used in combination with the cleaning agent for medical instruments according to the present embodiment. From the viewpoint of enzyme stability, it is preferable to separately prepare a cleaning agent containing a protease (B-1) and use it in combination immediately before or during washing.
  • Amylase (B-2) includes those of bacterial or fungal origin. Also included are chemically or genetically modified variants. Examples of amylase (B-2) are described in detail in British Patent No. 1,296,839. Examples thereof include ⁇ -amylase obtained from a special strain of B. licheniformis. Examples of commercially available amylase (B-2) include Duramyl, Termamyl, Fungamyl and BAN manufactured by Novozymes, and Rapidase and Maxamyl P manufactured by Gist-Brocades.
  • Lipase (B-3) includes those of bacterial or fungal origin. Also included are chemically or genetically modified variants. Examples of lipases include Humicola langinosa lipase (European Patent No. 258 068 and European Patent No. 30 216), Rhizomucor miehei lipase and Candida (Candida). Patent No. 238, 023), C.I. C. ntarctica lipases A and B, Pseudomonas lipases (European Patent No. 214, 761), P. et al. P. pseudoalcaligenes and P. pseudoalcaligenes. Alcaligenes lipase (European Patent No. 218, 272), P. et al. P.
  • cepasia lipase European Patent No. 331, 376
  • B.I. B. subtilis lipase Dartois et al. (1993), Biochemica et Biophysica Acta1131,253-260
  • B.I. B. stearothermophilus lipase Japanese Patent Publication No. 64-744922
  • B. B. pumilus lipase International Publication No. 91/16422
  • Examples of commercially available lipase (B-3) include M1 Lipase, Luma fast and Lipomax from Genecore, Lipase and Lipase Ultra from Novozymes, and Lipase P "Amano" from Amano Enzyme.
  • Cellulase (B-4) includes those of bacterial or fungal origin. Also included are chemically or genetically modified variants. Cellulases include those disclosed in US Pat. No. 4,435,307 as fungal cellulases produced from Humicola insolence.
  • Examples of commercially available cellulases include Cellulase of Novozymes Co., Ltd. and KAC-500 (B) of Kao Corporation produced by the strain of Humicola insolence.
  • protease (B-1) is preferable from the viewpoint of detergency.
  • the enzyme (B) contained in the cleaning agent for medical instruments can contain two or more types.
  • the combination containing two or more kinds include a combination containing two or more kinds of protease, protease and amylase, protease and lipase, or protease and amylase and lipase.
  • the content (% by mass) of the enzyme (B) contained in the cleaning agent for medical instruments is 0% by mass or more and 10% by mass with respect to the mass of the cleaning agent for medical instruments from the viewpoint of detergency.
  • the following is preferable, more preferably 0.05% by mass or more and 5% by mass or less, and particularly preferably 0.1% by mass or more and 3% by mass or less.
  • any of aminocarboxylic acid type, organic acid type, phosphonic acid type, phosphoric acid type and polycarboxylic acid type can be used.
  • aminopolyacetic acids such as nitrilotriacetic acid, iminodiacetic acid, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid, glycol etherdiaminetetraacetic acid, hydroxyethyliminodiacetic acid, triethylenetetraaminehexacetic acid, diencoric acid, etc.
  • Organic acids such as salts, diglycolic acid, oxydisuccinic acid, carboxymethyloxysuccinic acid, citric acid, lactic acid, tartrate acid, oxalic acid, malic acid, gluconic acid, carboxymethyl succinic acid, carboxymethyl tartrate acid, glutamate diacetic acid, etc.
  • the chelating agent (C) is preferably one or more selected from aminopolyacetic acid and a salt thereof, and more preferably one or two selected from ethylenediaminetetraacetic acid (EDTA) and a salt thereof. That is all.
  • Examples of the counterion of these salts include alkali metals, quaternary amines, alkanolamines, etc., but alkanolamine salts are preferable from the viewpoint of corrosion resistance to medical instruments. Further, a monoethanolamine salt is preferable. These can be used alone or in combination of two or more.
  • the content (% by mass) of the chelating agent (C) contained in the detergent for medical instruments is 0 with respect to the mass of the detergent for medical instruments from the viewpoint of the effect of removing protein stains and the cost. It is by mass% or more and 5% by mass or less, more preferably 0.005% by mass or more and 2% by mass or less, and further preferably 0.01% by mass or more and 1% by mass or less.
  • an acid equivalent amount is used as the content of the chelating agent (C).
  • a monosaccharide, a polysaccharide or a boron compound can be used as the enzyme stabilizer (D).
  • the monosaccharide and polysaccharide may be substituted or unsubstituted, and may be branched or linear. Examples of monosaccharides and polysaccharides include dextrin, glucose, mannose and the like.
  • the boron compound may be substituted or unsubstituted. Examples of the boron compound include boric acid, diboron trioxide, boronic acid, and salts thereof.
  • the content (mass%) of the enzyme stabilizer (D) contained in the cleaning agent for medical instruments is 0% by mass or more 10 with respect to the mass of the cleaning agent for medical instruments from the viewpoint of detergency. It is preferably 0.05% by mass or more, more preferably 0.05% by mass or more and 5% by mass or less, and particularly preferably 0.1% by mass or more and 3% by mass or less.
  • the anticoagulant (E) includes a sugar (E-1), a nonionic surfactant (E-2), an organic acid or a salt thereof (E-3), an inorganic oxo acid or a salt thereof (E-4). , Glycerin (E-5) is included.
  • the sugar (E-1) includes allose, altrose, mannose, growth, idose, galactose, tarose, monosaccharides having 3 to 5 carbon atoms, ketose having 6 carbon atoms, polysaccharides having disaccharides or more, and 4 carbon atoms. Examples thereof include ⁇ 12 sugar alcohols. Examples of monosaccharides having 3 to 5 carbon atoms include glyceraldehyde, erythrulose, erythrose, ribose, xylulose, and xylulose. Examples of ketose having 6 carbon atoms include fructose and sorbose.
  • disaccharide or higher polysaccharide examples include sucrose, lactose, trehalose, cellobiose, sophorose, raffinose, maltotriose, carboxylmethylcellulose, starch, pullulan, pectin, glucomannan and the like.
  • sugar alcohols having 4 to 12 carbon atoms include sorbitol, xylitol, pentaerythritol, maltitol, lactitol, sucralose and the like.
  • non-surface active agent (E-2) examples include higher alcohol alkylene oxide adduct, alkyl (or alkenyl) phenol alkylene adduct adduct, styrated phenol alkylene oxide adduct, styrated alkyl phenol alkylene adduct adduct, and higher alkyl (or higher alkyl (or alkenyl) adduct.
  • Higher alkenyl) amine alkylene oxide adduct fatty acid alkylene oxide adduct, fatty acid amide alkylene oxide adduct, polypropylene glycol alkylene oxide adduct, (mono or poly) glycerol fatty acid adduct or alkylene oxide adduct thereof, sucrose fatty acid ester or its Examples thereof include an alkylene oxide adduct, a sorbitan fatty acid ester, or an alkylene oxide adduct thereof.
  • the higher alcohol is usually a linear or branched unsaturated or saturated higher alcohol having 8 to 24 carbon atoms
  • the alkyl or alkenylphenol is usually a linear or branched alkyl group or alkenyl group having 6 to 22 carbon atoms
  • the higher alkyl or higher alkenylamine is usually a linear or branched higher alkyl or higher alkenylamine having 8 to 24 carbon atoms
  • the fatty acid is usually an unsaturated or saturated fatty acid having 8 to 24 carbon atoms.
  • the weight average molecular weight of polypropylene glycol is 900 to 5000.
  • alkyleneoxy group of the alkylene oxide adduct examples include ethyleneoxy group, propyleneoxy group, butyleneoxy group, and styreneoxy group, which may be used alone or in combination of two or more.
  • the addition form of the alkylene oxide is not limited, and examples thereof include random addition, block addition, and a method of mixing random and block.
  • the number of moles of the alkylene oxide adduct added is 1 to 1000.
  • Examples of the organic acid or a salt thereof (E-3) include amino acids, aminocarboxylic acids, keto acids, oxycarboxylic acids, polycarboxylic acids, saturated or unsaturated fatty acids having 1 to 24 carbon atoms, and salts thereof. ..
  • Examples of the organic acid include organic compounds having an acidic group such as a carboxy group, a sulfo group, a phosphoric acid group, a thiol group, and a phenolic hydroxyl group in the molecule, and examples of these salts include alkali metal salts. Examples thereof include ammonium salts and alkanolamine salts.
  • examples of the organic compound having a carboxy group include amino acids, aminocarboxylic acids, keto acids, oxycarboxylic acids, polycarboxylic acids, saturated or unsaturated fatty acids having 1 to 24 carbon atoms, and the like.
  • examples of the organic compound having a sulfo group include benzenesulfonic acid, linear alkylbenzenesulfonic acid, ⁇ -olefin sulfonic acid, sulfuric acid monoester and the like.
  • examples of the organic compound having a phosphoric acid group include adenylic acid, ethidroic acid, phosphinic acid monoester salt, phosphoric acid monoester, and phosphoric acid diester.
  • Examples of the organic compound having a thiol group include 4-mercaptoacetophenone, thiosalicylic acid, thiobenzoic acid, thioglycolic acid and the like.
  • Examples of the organic compound having a phenolic hydroxyl group include phenol, 2-naphthol, catechol and the like.
  • Examples of the alkali metal salt include sodium salt and potassium salt.
  • Examples of the alkanolamine salt include monoethanolamine salt, diethanolamine salt, triethanolamine salt and the like.
  • Examples of the inorganic oxoacid or a salt thereof (E-4) include phosphates, hypophosphates, pyrophosphates, polyphosphates, sulfates and the like.
  • Examples of the inorganic oxo acid are oxo acids such as phosphorus, sulfur, nitrogen, boron, chlorine, bromine, iodine and silicon, and examples of these salts include alkali metal salts, ammonium salts and alkanolamine salts.
  • examples of phosphorus oxoacids include hypophosphite, phosphite, phosphoric acid, pyrophosphoric acid, and polyphosphates having a degree of polymerization of 3 to 6.
  • sulfur oxoacids include hyposulfuric acid, sulfite, sulfuric acid, persulfuric acid, pyrosulfuric acid, disulfurous acid, thiosulfuric acid, sulfamic acid, amidosulfuric acid, and dithionous acid.
  • examples of the oxo acid of nitrogen include nitrite and nitric acid.
  • examples of the oxo acid of boron include metaboric acid, boric acid, and perboric acid.
  • Examples of the oxo acid of chlorine include hypochlorous acid, chloric acid, chloric acid, perchloric acid and the like.
  • Examples of the bromic acid of bromine include hypobromous acid, bromous acid, bromic acid, and perbromic acid.
  • Examples of the oxo acid of iodine include hypoiodous acid, iodic acid, and periodic acid.
  • Examples of the oxo acid of silicon include ortho-silicic acid, meta-silicic acid, meta-silicic acid and the like.
  • Examples of the alkali metal salt include sodium salt, potassium salt and the like, and examples of the alkanolamine salt include monoethanolamine salt, diethanolamine salt, triethanolamine salt and the like.
  • the cleaning agent for medical instruments can clean blood stains more efficiently by containing the anticoagulant (E).
  • the content (mass%) of glycerin (E-5) contained in the cleaning agent for medical instruments is 0% by mass with respect to the mass of the cleaning agent from the viewpoint of the blood coagulation preventing effect and the coagulating blood dissolving effect. It is 80% by mass or less.
  • silicate can be used as the metal corrosion inhibitor (F).
  • the silicate include alkali metal silicates.
  • the alkali metal silicate a compound in which n of M 2 O ⁇ nSiO 2 is 0.3 to 5 is used. Further, a more preferable value of n is 1 to 3. From the viewpoint of light metal corrosion suppression performance, n is preferably 0.3 or more, and from the viewpoint of preventing scale generation derived from silicic acid, n is preferably 5 or less.
  • the alkali metal silicate include potassium orthosilicate, sodium orthosilicate, sodium sesquisilicate, potassium sesquisilicate, sodium metasilicate, potassium metasilicate, and sodium No. 1 sodium silicate and sodium No.
  • the content (mass%) of the metal corrosion inhibitor (F) contained in the cleaning agent for medical instruments is 0% by mass or more and 10% by mass with respect to the mass of the cleaning agent from the viewpoint of corrosion suppression performance. % Or less is preferable.
  • the low molecular weight polyol (G) contains an alcohol compound having at least two hydroxyl groups and having 2 to 30 carbon atoms.
  • Examples of the low molecular weight polyol (G) include ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, propanediol, butanediol, methylpropanediol, pentanediol, and methylbutane.
  • butenediol methylenepropanediol, butinediol, hexenediol, methylpentenediol, hexadienediol, octenediol, dimethylhexenediol, decenediol, dimethyloctenediol, tetradecenediol, hydroxyoctadesenol, pentynediol, Hexindiol, methylpentindiol, heptindiol, dimethylpentindiol, dimethylhexindiol, decinediol, dimethyloctinediol, tetramethyloctinediol, tetramethyldecinediol, tetramethyldodecinediol, tetraisopropyloctinediol , Unsaturated diols such as diethyltetradecine diol and the like.
  • aliphatic cyclic diols such as cyclopentanediol, cyclohexanediol, cycloheptandiol, norbornandiol, cyclooctanediol, cyclodecanediol, cyclooctenediol, decalindiol, limonene glycol, terpendiol, bicyclohexanediol, and cyclododecanediol, etc.
  • aliphatic cyclic diols such as cyclopentanediol, cyclohexanediol, cycloheptandiol, norbornandiol, cyclooctanediol, cyclodecanediol, cyclooctenediol, decalindiol, limonene glycol, terpendiol, bicyclohe
  • Triol alcohol and the like can be mentioned.
  • erythritol pentaerythritol, pentatetrol, hexatetrol, pentantetrol, hexanetetrol, diglycerin, sorbitan, N, N, N', N'-tetrakis (2-hydroxypropyl) ethylenediamine, N, N , N', N'-tetrakis (hydroxyethyl) ethylenediamine and other tetrahydric alcohols and the like.
  • Examples thereof include pentahydric alcohols such as adonitol, arabitol, xylitol and triglycerin, and hexahydric alcohols such as dipentaerythritol, sorbitol, mannitol, iditol, inositol, darcitol, tarose and allose.
  • pentahydric alcohols such as adonitol, arabitol, xylitol and triglycerin
  • hexahydric alcohols such as dipentaerythritol, sorbitol, mannitol, iditol, inositol, darcitol, tarose and allose.
  • N-substituted diethanolamines such as N-methyldiethanolamine, N-ethyldiethanolamine, N-propyldiethanolamine, N-isopropyldiethanolamine, N-butyldiethanolamine, N-cyclohexyldiethanolamine, N- (2-ethylhexyl) diethanolamine and the like can be mentioned. Be done.
  • N-methyldiisopropanolamine, N-ethyldiisopropanolamine, N-propyldiisopropanolamine, N-isopropyldiisopropanolamine, N-butyldiisopropanolamine, N-cyclohexyldiisopropanolamine, N- (2-ethylhexyl) ) N-substituted diisopropanolamines such as diisopropanolamine and the like can be mentioned.
  • N-di-substituted aminopropanediols such as dimethylaminopropanediol, diethylaminopropanediol, dipropylaminopropanediol, diisopropylaminopropanediol and dibutylaminopropanediol can be mentioned.
  • These exemplified low molecular weight polyols (G) may also include position isomer compounds.
  • the content (mass%) of the low molecular weight polyol (G) contained in the cleaning agent for medical instruments is 0% by mass or more and 80% by mass with respect to the mass of the cleaning agent for medical instruments from the viewpoint of detergency. It is preferably mass% or less.
  • Cleaning aids (builders) (H) include polycarboxylic acids (acrylic acid homopolymers, maleate homopolymers, etc.), polyvalent carboxylates (citric acid, malic acid, etc.), and alkaline builders (caustic soda). , Soda ash, ammonia, triethanolamine, sodium tripolyphosphate, sodium silicate, etc.) and the like.
  • the content (% by mass) of the builder (H) contained in the cleaning agent is preferably 0% by mass or more and 20% by mass or less with respect to the mass of the cleaning agent for medical instruments from the viewpoint of detergency. ..
  • the defoaming agent (I) examples include silicone-based defoaming agents, polyoxyalkylene-based defoaming agents, and mineral oil-based defoaming agents.
  • the content (mass%) of the defoaming agent (I) contained in the cleaning agent for medical instruments is 0% by mass or more 10 with respect to the mass of the cleaning agent for medical instruments from the viewpoint of detergency. It is preferably mass% or less.
  • the pH adjuster (J) examples include sulfuric acid, hydrochloric acid, citric acid, lactic acid, pyruvic acid, formic acid, sodium chloride, potassium chloride, monoethanolamine and diethanolamine.
  • the content (mass%) of the pH adjuster (J) contained in the cleaning agent for medical instruments is 0% by mass or more 25 with respect to the mass of the cleaning agent for medical instruments from the viewpoint of detergency. It is preferably 0% by mass or more, more preferably 0% by mass or more and 15% by mass or less, and particularly preferably 0% by mass or more and 10% by mass or less.
  • the concentration of the fluoroalcohol when acting on the protein aggregate may be 0.1% by mass or more, preferably 1% by mass or more, and further preferably 8% by mass or more.
  • the concentration of the fluoroalcohol when acting on the protein aggregate is more preferably 29% by mass or more.
  • the time for the fluoroalcohol to act on the protein aggregate is not particularly limited.
  • the time for the fluoroalcohol to act on the protein aggregate is effective even for a short time.
  • the time for allowing the fluoroalcohol to act on the protein aggregate may be 30 seconds or longer, preferably 1 minute or longer, more preferably 20 minutes or longer, and particularly preferably 30 minutes or longer.
  • the cleaning agent for medical instruments may contain an active ingredient of a commercially available disinfectant as an additive.
  • the active ingredient of a commercially available disinfectant include an active ingredient of a high-level disinfectant (for example, glutarualdehyde, orthophthalaldehyde, peracetic acid or peracetic acid), and an active ingredient of a medium-level disinfectant (hypochlorite).
  • a high-level disinfectant for example, glutarualdehyde, orthophthalaldehyde, peracetic acid or peracetic acid
  • a medium-level disinfectant hyperochlorite
  • Sodium, ethanol, povidone iodine active ingredients of low-level disinfectants (quaternary ammonium, chlorhexidine gluconate).
  • the content (mass%) of these active ingredients contained in the cleaning agent for medical instruments is 0% by mass or more and 99.9% by mass or less with respect to the mass of the cleaning agent for medical instruments. It is also preferable, 0% by mass or more and 99% by mass
  • the fluoroalcohol contained in the cleaning agent for medical instruments is effective for cleaning medical instruments contaminated with protein aggregates or to which protein aggregates are attached.
  • HFIP can lyse organic substances such as proteins and cell tissues. Therefore, it becomes easy to remove organic substances such as proteins and cell tissues adhering to the object to be cleaned, and the cleaning power can be improved.
  • HFIP is a stable low molecular weight compound having a molecular weight of 168 and has high storage stability. Further, since it has good thermal stability, the cleaning temperature is not limited, and the cleaning power can be further improved.
  • HFIP is less corrosive to metals and has less effect on the material of the object to be cleaned. Furthermore, HFIP is nonflammable and easy to manage safety in use.
  • the cleaning agent for medical devices according to the present embodiment is used for cleaning various medical devices (including, for example, an endoscope), as well as for cleaning objects including animal medical devices, meat processing tools, and cooking tools. Can be used.
  • the present invention is not limited to this, and can be widely applied as a countermeasure against infection of protein aggregates. For example, it can be used for cleaning an operating room in the medical field, linen such as beds and sheets, and cleaning an object including disinfection of human hands.
  • the cleaning agent for medical instruments may be, for example, manual cleaning (including immersion cleaning), ultrasonic cleaning, jet cleaning, shower cleaning, steam cleaning, vacuum cleaning, degassing cleaning, washer-disinfector, or It can be used in any of these two or more combinations of cleaning methods, but is not limited thereto.
  • a cleaning method using a washer-disinfector generally consists of steps of pre-cleaning, main cleaning, rinsing, and disinfection.
  • the cleaning agent for medical instruments according to the present embodiment can be used for pre-cleaning and main cleaning, and can also be used in combination with other cleaning agents for pre-cleaning or main cleaning.
  • the permissible concentration of the fluorine-based alcohol contained in the cleaning agent for medical instruments is the same as the concentration at which the protein aggregate can be altered, and specifically, it may be 0.1% by mass or more. 1, 1% by mass or more is preferable, 8% by mass or more is more preferable, and 29% by mass or more is most preferable.
  • the cleaning agent for medical instruments is used in the pre-cleaning step and / or the main cleaning step of the cleaning method to efficiently obtain biological blood or body fluid, fat, prion protein and infectious amyloid from the object. It is possible to remove proteins such as proteins, organic substances such as cell tissues, microorganisms, viruses, and the like.
  • the cleaning agent for medical instruments is not limited to the above-mentioned uses, and may be used in the same manner as known antiviral agents, antibacterial agents, bactericidal agents, disinfectants, fungicides, etc., depending on the object to be cleaned. can do.
  • a method of spraying on an object to be cleaned a method of applying, a method of impregnating the object, a method of immersing the object, a method of exposing the object to high-pressure steam, and the like, which are usually adopted, can be used as they are. ..
  • the temperature at which the fluorine-based alcohol contained in the cleaning agent for medical instruments alters the protein aggregate is not particularly limited, and a temperature of room temperature or higher (for example, 20 ° C or higher) is preferable.
  • a temperature of room temperature or higher for example, 20 ° C or higher
  • the temperature at which the fluoroalcohol and the protein aggregate are brought into contact with each other the more easily the protein aggregate is altered.
  • the temperature may be higher than the boiling point of the fluoroalcohol, that is, vaporized into vapor and brought into contact with the protein aggregate.
  • the optimum temperature can be selected depending on the solvent and additives contained in the cleaning agent for medical instruments.
  • FIG. 1 is a schematic view showing a cleaning device 1 according to an embodiment of the present invention.
  • the cleaning device 1 may be for cleaning a medical device.
  • the cleaning device 1 includes a cleaning tank 10 having a storage unit 20 for accommodating an object (medical device), and a cleaning agent supply device 40 for supplying a cleaning agent for medical devices into the cleaning tank 10. , Equipped with.
  • the washing tank 10 has a water storage unit 12 that stores wash water under the storage unit 20, and a water supply source and water supply as a washing water supply means for supplying water and hot water sent from the hot water supply source to the water storage unit 12 as wash water.
  • the cleaning pump 18 that sends the cleaning water of the water storage unit 12 to the cleaning nozzle 22.
  • the medical equipment is cleaned by the preliminary cleaning step, the main cleaning step, and the rinsing cleaning step, and then disinfected with boiling water by the disinfection step.
  • the cleaning agent for medical instruments can be used for pre-cleaning and main cleaning, and can also be used for pre-cleaning or main cleaning in combination with other cleaning agents.
  • the cleaning agent for medical instruments contains a plurality of components, some of the components or each component can be used for pre-cleaning or main cleaning from separate lines.
  • the cleaning device 1 When the cleaning process is started, the cleaning device 1 first executes the preliminary cleaning process.
  • the cleaning device 1 opens the water supply valve and starts the water supply treatment in the preliminary cleaning process.
  • the water from the water supply source is sent out to the water storage unit 12 of the washing tank 10 through the water supply pipe 14.
  • the cleaning device 1 determines whether or not the water in the water storage unit 12 has reached a predetermined water level by detecting the float switch.
  • the cleaning device 1 closes the water supply valve and ends the water supply process.
  • the water in the pre-cleaning step may be at room temperature (eg 20 ° C.).
  • the cleaning device 1 supplies the cleaning agent into the cleaning tank 10 by the cleaning agent supply device 40, and operates the cleaning pump 18 for a predetermined time.
  • the cleaning water in the water storage unit 12 is sent to the cleaning nozzle 22 via the circulation pipe, and the cleaning nozzle 22 injects the cleaning water onto the medical device while rotating to perform cleaning.
  • the cleaning water containing the cleaning agent in the cleaning tank 10 falls and returns to the water storage unit 12.
  • the cleaning device 1 operates the drainage pump for a predetermined time as the wastewater treatment.
  • the washing water in the water storage unit 12 is discharged to the outside of the machine through the drain pipe 34.
  • the cleaning device 1 executes the main cleaning process.
  • the cleaning device 1 opens the water supply valve and the hot water supply valve to start the water supply process in the main cleaning step.
  • the water from the water supply source and the hot water from the hot water supply source are sent out to the water storage unit 12 of the washing tank 10 through the water supply pipe 14 and the hot water supply pipe 16.
  • the cleaning device 1 determines whether or not the water in the water storage unit 12 has reached a predetermined water level by detecting the float switch.
  • the cleaning device 1 closes the water supply valve and the hot water supply valve to end the water supply process.
  • the water in this washing step is preferably 25 ° C. or higher.
  • the cleaning device 1 supplies the cleaning agent into the cleaning tank 10 by the cleaning agent supply device 40, and operates the cleaning pump 18 for a predetermined time.
  • the cleaning water in the water storage unit 12 is sent to the cleaning nozzle 22 via the circulation pipe, and the cleaning nozzle 22 injects the cleaning water onto the medical device while rotating to perform cleaning.
  • the cleaning water containing the cleaning agent in the cleaning tank 10 falls and returns to the water storage unit 12.
  • the cleaning device 1 operates the drainage pump for a predetermined time as the wastewater treatment.
  • the washing water in the water storage unit 12 is discharged to the outside of the machine through the drain pipe 34.
  • This cleaning step may be executed multiple times.
  • the main cleaning treatment may be performed a plurality of times by using different cleaning agents.
  • the main cleaning treatment may be performed with cleaning water at 60 ° C. or higher.
  • the main cleaning treatment may be performed with cleaning water at about 30 to 40 ° C. (for example, 37 ° C.).
  • the cleaning device 1 executes the rinsing process.
  • the washing device 1 opens the hot water supply valve and starts the hot water supply process in the rinsing step.
  • the hot water of the hot water supply source is sent to the water storage unit 12 of the washing tank 10 through the hot water supply pipe 16.
  • the cleaning device 1 determines whether or not the hot water in the water storage unit 12 has reached a predetermined water level by detecting the float switch. When the cleaning device 1 determines that the hot water in the water storage unit 12 has reached a predetermined water level, the cleaning device 1 closes the hot water supply valve and ends the hot water supply process.
  • the cleaning device 1 operates the cleaning pump 18 for a predetermined time as a rinsing process.
  • the hot water in the water storage unit 12 is sent to the cleaning nozzle 22 via the circulation pipe, and the cleaning nozzle 22 injects hot water onto the medical device while rotating to wash away the cleaning water containing the cleaning agent.
  • the cleaning device 1 operates the drainage pump for a predetermined time as the wastewater treatment.
  • the rinse water in the water storage unit 12 is discharged to the outside of the machine through the drain pipe 34.
  • the cleaning device 1 executes the disinfection process.
  • the cleaning device 1 opens the hot water supply valve and starts the hot water supply process in the disinfection step.
  • the hot water of the hot water supply source is sent to the water storage unit 12 of the washing tank 10 through the hot water supply pipe 16.
  • the cleaning device 1 determines whether or not the hot water in the water storage unit 12 has reached a predetermined water level by detecting the float switch.
  • the cleaning device 1 closes the hot water supply valve and ends the hot water supply process.
  • the boiling water in the disinfection step is preferably 60 ° C. or higher.
  • the cleaning device 1 operates the cleaning pump 18 for a predetermined time as a disinfection process.
  • the hot water in the water storage unit 12 is sent to the cleaning nozzle 22 via the circulation pipe, and the cleaning nozzle 22 injects the hot water into the medical device while rotating.
  • the cleaning device 1 operates the drainage pump for a predetermined time as the wastewater treatment.
  • the hot water in the water storage unit 12 is discharged to the outside of the machine through the drain pipe 34.
  • the cleaning device 1 efficiently removes protein aggregates from an object by supplying the cleaning agent for medical equipment according to the present embodiment into the cleaning tank 10 by the cleaning agent supply device 40, and at the same time, living body-derived blood and blood and the like. It can remove proteins such as body fluids, fats, prion proteins and infectious amyloids, organic substances such as cell tissues, microorganisms, viruses and the like.
  • the cleaning device 1 can also use a cleaning agent for medical instruments according to the present embodiment and a known cleaning agent in combination.
  • the cleaning device 1 can also be used for cleaning animal medical utensils, meat processing utensils, and cooking utensils.
  • soil cleaning agent The molecular structure altering agent according to the present invention described above can be used as a soil cleaning agent in one embodiment.
  • PrP Sc may flow out into the environment from the carcasses of animals that have developed BSE, sheep scrapie, CWD, etc., and pollute the soil. At this time, no drug is known that can effectively remove protein aggregates from soil.
  • the soil cleaning agent may also include common additives described as known techniques. These also include pesticides, fertilizers, fungicides, disinfectants, etc. used in soil.
  • the soil cleaning agent contains the above-mentioned molecular structure altering agent according to the present invention, and may further contain a solvent.
  • the solvent can be selected from substances that can dilute the molecular structure altering agent, and examples thereof include the same solvents as those mentioned in the above-mentioned cleaning agents for medical devices. These may be one or more, but are not limited thereto.
  • the content (% by mass) of the solvent contained in the soil cleaning agent may be 0% by mass or more and 99.9% by mass or less with respect to the mass of the soil cleaning agent from the viewpoint of cleaning property. Often, 0% by mass or more and 99% by mass or less is preferable, 0% by mass or more and 92% by mass or less is particularly preferable, and 0% by mass or more and 71% by mass or less is further preferable.
  • the soil cleaning agent may contain additives in addition to the molecular structure altering agent and the solvent.
  • Additives that can be added to soil cleaning agents include surfactants, enzymes, enzyme stabilizers, metal corrosion inhibitors, low molecular weight polyols, cleaning aids (builders), defoamers, pH adjusters, fragrances, and colorants. , Antioxidants, preservatives, bleaching agents, bleaching activators, corrosion inhibitors, dispersants, thickeners, viscosity regulators, etc., but are not limited thereto.
  • the soil cleaning agent may contain one or more additives. In one embodiment, the soil cleaning agent can further improve the cleaning power by containing a molecular structure altering agent, a solvent, and the above-mentioned additives.
  • Examples of the surfactant (A) include the same surfactants (A) as those mentioned in the above-mentioned cleaning agents for medical devices.
  • As the surfactant (A) one kind or two or more kinds can be used.
  • the content (mass%) of the surfactant (A) contained in the soil cleaning agent is preferably 0% by mass or more and 10% by mass or less with respect to the mass of the soil cleaning agent from the viewpoint of detergency, and more preferably. It is 0.1% by mass or more and 5% by mass or less.
  • Examples of the enzyme (B) include the same enzymes (B) as those mentioned in the above-mentioned cleaning agents for medical devices.
  • As the enzyme (B), one type or two or more types can be used.
  • the content (mass%) of the enzyme (B) contained in the soil cleaning agent is preferably 0% by mass or more and 10% by mass or less with respect to the mass of the soil cleaning agent from the viewpoint of cleanability. More preferably, it is 0.05% by mass or more and 5% by mass or less, and particularly preferably 0.1% by mass or more and 3% by mass or less.
  • the enzyme stabilizer (C) examples include the same enzyme stabilizer (D) mentioned in the above-mentioned cleaning agent for medical devices.
  • the enzyme stabilizer (C) one kind or two or more kinds can be used.
  • the content (mass%) of the enzyme stabilizer (C) contained in the soil cleaning agent is 0% by mass or more and 10% by mass or less with respect to the mass of the soil cleaning agent from the viewpoint of cleanability. It is preferable, more preferably 0.05% by mass or more and 5% by mass or less, and particularly preferably 0.1% by mass or more and 3% by mass or less.
  • the metal corrosion inhibitor (D) examples include the same as the metal corrosion inhibitor (F) mentioned in the above-mentioned cleaning agent for medical devices.
  • the metal corrosion inhibitor (D) one type or two or more types can be used.
  • the content (mass%) of the metal corrosion inhibitor (F) contained in the soil cleaning agent is 0% by mass or more and 10% by mass with respect to the mass of the soil cleaning agent from the viewpoint of corrosion suppression performance. The following is preferable.
  • Examples of the low-molecular-weight polyol (E) include those similar to the low-molecular-weight polyol (G) mentioned in the above-mentioned cleaning agent for medical devices.
  • As the low molecular weight polyol (E) one kind or two or more kinds can be used.
  • the content (mass%) of the low molecular weight polyol (E) contained in the soil cleaning agent is 0% by mass or more and 80% by mass or less with respect to the mass of the soil cleaning agent from the viewpoint of detergency. preferable.
  • the cleaning aid (builder) (F) examples include the same cleaning aid (builder) (H) mentioned in the above-mentioned cleaning agent for medical devices.
  • the builder (F) one type or two or more types can be used.
  • the content (mass%) of the builder (F) contained in the soil cleaning agent is preferably 0% by mass or more and 20% by mass or less with respect to the mass of the soil cleaning agent from the viewpoint of detergency.
  • Examples of the defoaming agent (G) include those similar to the defoaming agent (I) mentioned in the above-mentioned cleaning agent for medical devices.
  • the content (mass%) of the defoaming agent (G) contained in the soil cleaning agent is 0% by mass or more and 10% by mass or less with respect to the mass of the soil cleaning agent from the viewpoint of detergency. preferable.
  • Examples of the pH adjuster (H) include those similar to the pH adjuster (J) mentioned in the above-mentioned cleaning agent for medical devices.
  • the content (mass%) of the pH adjuster (H) contained in the soil cleaning agent is 0% by mass or more and 25% by mass or less with respect to the mass of the soil cleaning agent from the viewpoint of cleanability. It is preferable, more preferably 0% by mass or more and 15% by mass or less, and particularly preferably 0% by mass or more and 10% by mass or less.
  • the concentration of the fluoroalcohol when acting on the protein aggregate may be 0.1% by mass or more, preferably 1% by mass or more, and further preferably 8% by mass or more.
  • the concentration of the fluoroalcohol when acting on the protein aggregate is more preferably 29% by mass or more.
  • the time for the fluoroalcohol to act on the protein aggregate is not particularly limited.
  • the time for the fluoroalcohol to act on the protein aggregate is effective even for a short time.
  • the time for allowing the fluoroalcohol to act on the protein aggregate may be 30 seconds or longer, preferably 1 minute or longer, more preferably 20 minutes or longer, and particularly preferably 30 minutes or longer. In order to increase the effect, it is also preferable to use a plurality of times in stages with intervals of use on a daily or weekly basis or even on a seasonal basis.
  • the soil cleaning agent may contain the active ingredient of a commercially available disinfectant as an additive.
  • the active ingredient of the commercially available disinfectant include the same active ingredients of the commercially available disinfectant mentioned in the above-mentioned cleaning agents for medical devices.
  • the content (% by mass) of these active ingredients contained in the soil cleaning agent may be 0% by mass or more and 99.9% by mass or less with respect to the mass of the soil cleaning agent, and is 0. It is preferably 0% by mass or more and 99% by mass or less, particularly preferably 0% by mass or more and 92% by mass or less, and further preferably 0% by mass or more and 71% by mass or less.
  • the fluoroalcohol contained in the soil cleaning agent is effective for cleaning soil contaminated with protein aggregates.
  • HFIP is a stable low molecular weight compound having a molecular weight of 168 and has high storage stability. Further, since it has good thermal stability, the cleaning temperature is not limited, and the cleaning power can be further improved. Furthermore, HFIP is nonflammable and easy to manage safety in use.
  • the soil cleaning agent according to the present embodiment can be used to clean soil contaminated with protein aggregates or soil that may be contaminated.
  • the soil may be washed prophylactically with the soil cleaning agent according to the present embodiment.
  • the soil cleaning agent may be diluted with the above solvent and used for cleaning.
  • the soil cleaning agent or solvent and the soil cleaning agent according to the present embodiment are added to the soil to be cleaned, mixed, and the washed soil is separated and dried to alter the protein agglomerates.
  • the soil can be washed.
  • the concentration of the fluorinated alcohol or the compound represented by the general formula (1) may be 0.01% by mass or more, preferably 0.1% by mass or more, and 1% by mass or more. Is particularly preferable. It can be adjusted arbitrarily while considering the degree of soil contamination at the time of use, the time of contamination, the surrounding environment of the soil, and the like.
  • the fluoroalcohol or the compound represented by the general formula (1) can also be used as a soil fumigant.
  • the soil can be washed by fumigating the soil suspected of being contaminated with a fluorine-based alcohol or a soil fumigant containing a compound represented by the general formula (1).
  • HFIP Central Glass Co., Ltd., purity 99% or higher
  • ⁇ Cells derived from mouse neuroblastoma> In cell cultures from murine neuroblastoma, and Neuro 2a (N2a) cells producing normal prion protein (PrP C), the ScNeuro 2a (ScN2a) cells that persist producing an abnormal prion protein (PrP Sc) 2
  • a type of cell line (ATCC) was prepared. The two cell lines were humidified in Eagle's Minimal Essential Medium (E-MEM) (Fuji Film Wako Pure Chemical Industries, Ltd.) containing 10% FBS (fetal bovine serum) and 100 Units / ml Penicillin, 100 ⁇ g / ml Streptomycin. The cells were cultured under 37 ° C. and 5% CO 2 conditions.
  • a cell culture dish (AGC Techno Glass Co., Ltd.) and a cell culture microplate (6 wells or 24 wells, AGC Techno Glass Co., Ltd.) were used as cell culture vessels.
  • Example 1 In the evaluation of susceptibility to HFIP described above, various media having final concentrations of HFIP in the medium of 0 mM, 10 mM, 20 mM, 25 mM, 30 mM, and 40 mM were used. Here, “M” indicates a molar concentration (mol / L). These were added to ScN2a cells and cell culture was carried out for 24 hours.
  • the upper limit of the concentration of HFIP in which N2a cells can survive was 25 mM
  • the upper limit of the concentration of HFIP in which ScN2a cells could survive was 20 mM.
  • This result indicates that N2a cells and ScN2a cells have different sensitivities to HFIP.
  • This difference in susceptibility to HFIP indicates that HFIP can be used to detect abnormally structured prion proteins. Therefore, it has been shown that it can be suitably used for simple screening and diagnosis of protein misfolding diseases having a ⁇ -sheet structure or an amyloid structure.
  • Example 2 The medium of ScN2a cells was replaced with a medium having a final concentration of HFIP of 6 mM and incubated for 24 hours.
  • Dissolution buffer for gel electrophoresis 150 mM Tris-HCl (Tris hydrochloride buffer) pH 6.8, 6% SDS (sodium dodecyl sulfate), 30% glycerol, 0.01% BPB (bromophenol blue)
  • DTT dithiotreitol
  • the gel after electrophoresis was transferred to a PVDF membrane (polyvinylidene fluoride).
  • PVDF film polyvinylidene fluoride
  • iBlot2 Transfer Stacks, PVDF, and regular size (Cat.IB24001) were used.
  • iBlot Gel Transfer Device (Thermo Fisher Scientific) was used, and energization was carried out at 20 V for 1 minute, 23 V for 4 minutes, and 25 V for 2 minutes for a total of 7 minutes.
  • the PVDF membrane after transfer was treated with PBS-Tween 20 (PBS-T) containing 5% (weight / volume%) skim milk for 30 minutes at room temperature (blocking), and anti-PrP diluted 1000-fold with PBS-T.
  • the antibody (Cat.
  • Example 2 The results of Western blotting of Example 2 are shown in # 5 to # 8 of FIG. 3, and the results of Western blotting of Comparative Example 2 are shown in # 1 to # 4 of FIG.
  • the molecular structure altering agent for protein aggregates in the present invention is usefully used for diagnostic purposes of protein misfolding diseases.
  • cleaning device 10 cleaning tank, 12 water storage section, 14 water supply pipe, 16 hot water supply pipe, 18 cleaning pump, 20 storage section, 22 cleaning nozzle, 34 drain pipe, 40 cleaning agent supply device, 100 inspection device, 110 input section, 120 detection unit, 130 storage unit, 140 display unit, 150 control unit, 160 calculation unit, 170 power supply device, 180 communication unit, 200 network, 300 server, 400 terminal

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Sustainable Development (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un agent d'altération de la structure moléculaire qui interagit spécifiquement avec des agrégats protéiques et détecte lesdits agrégats protéiques, et un procédé de détection d'agrégats protéiques. L'invention concerne en outre un agent de nettoyage et une procédé de nettoyage pour nettoyer le sol et un équipement médical contaminés par des agrégats protéiques. Cet agent d'altération de la structure moléculaire contient, en tant que composé qui détecte des agrégats protéiques, un alcool fluoré ou un composé représenté par la formule générale (1). (Dans la formule générale (1), a vaut 0 ou 1 ; si a = 1, alors R1 représente un atome d'hydrogène et R2 représente un groupe hydroxyle, ou R1 représente un groupe hydroxyle et R2 représente un atome d'hydrogène ; si a = 0, alors R2 représente un atome d'oxygène qui forme une liaison divalente avec un atome de carbone, R3 représente CHlClmFn, l, m et n représentant des entiers de 1 à 3 et l + m + n = 3, et R4 représente CHsCltFu, s, t et u représentant des entiers de 1 à 3 et s + t + u = 3).
PCT/JP2020/041521 2019-11-08 2020-11-06 Agent d'altération de la structure moléculaire pour la détection d'agrégats protéiques, procédé de détection associé, agent de nettoyage d'équipement médical, agent de nettoyage du sol et procédé de nettoyage du sol WO2021090910A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2019203527 2019-11-08
JP2019-203527 2019-11-08
JP2019-230526 2019-12-20
JP2019230526 2019-12-20

Publications (1)

Publication Number Publication Date
WO2021090910A1 true WO2021090910A1 (fr) 2021-05-14

Family

ID=75848108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/041521 WO2021090910A1 (fr) 2019-11-08 2020-11-06 Agent d'altération de la structure moléculaire pour la détection d'agrégats protéiques, procédé de détection associé, agent de nettoyage d'équipement médical, agent de nettoyage du sol et procédé de nettoyage du sol

Country Status (1)

Country Link
WO (1) WO2021090910A1 (fr)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS595240B2 (ja) * 1978-06-30 1984-02-03 クロエ・シミ 繊維材料の洗浄又は脱油用組成物
JPH0641591A (ja) * 1992-07-24 1994-02-15 Asahi Glass Co Ltd 洗浄溶剤組成物
JPH1012584A (ja) * 1996-06-27 1998-01-16 Mitsubishi Chem Corp 基体の表面処理方法及びそれに用いる有機錯化剤含有アンモニア水溶液
JPH10130695A (ja) * 1996-10-28 1998-05-19 Kao Corp 漂白剤組成物
JP2000501777A (ja) * 1997-02-19 2000-02-15 ミネソタ マイニング アンド マニュファクチャリング カンパニー メトキシ−パーフルオロプロパンの共沸組成物およびその使用
JP2004050109A (ja) * 2002-07-23 2004-02-19 Matsushita Electric Ind Co Ltd 部品の洗浄方法及び洗浄装置
JP2004157124A (ja) * 2002-11-06 2004-06-03 F Hoffmann La Roche Ag アミロイド定量法
JP2004529314A (ja) * 2000-10-27 2004-09-24 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア プリオン株を決定する方法
JP2004284996A (ja) * 2003-03-24 2004-10-14 Nicca Chemical Co Ltd 泡状アルコール組成物
JP2007314767A (ja) * 2006-03-31 2007-12-06 Ethicon Inc 医療器具前処理用泡の配合組成
JP2008535786A (ja) * 2005-02-28 2008-09-04 アルファベータ エイビー アミロイドベータ−ペプチドの凝集を低減する化合物
CN102879577A (zh) * 2012-11-01 2013-01-16 山东龙美生物医学科技有限公司 一种检测朊病毒的试剂盒及其制备方法
JP2013098303A (ja) * 2011-10-31 2013-05-20 Central Glass Co Ltd 洗浄乾燥剤およびそれを用いた基板の洗浄乾燥方法
JP2015511014A (ja) * 2012-03-13 2015-04-13 ヤンセン アルツハイマー イミュノセラピー アルツハイマー病の診断、予後および監視におけるオリゴマー型Ａβ
JP2019144220A (ja) * 2018-02-23 2019-08-29 学校法人麻布獣医学園 アミロイドタンパク質を抽出する試薬

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS595240B2 (ja) * 1978-06-30 1984-02-03 クロエ・シミ 繊維材料の洗浄又は脱油用組成物
JPH0641591A (ja) * 1992-07-24 1994-02-15 Asahi Glass Co Ltd 洗浄溶剤組成物
JPH1012584A (ja) * 1996-06-27 1998-01-16 Mitsubishi Chem Corp 基体の表面処理方法及びそれに用いる有機錯化剤含有アンモニア水溶液
JPH10130695A (ja) * 1996-10-28 1998-05-19 Kao Corp 漂白剤組成物
JP2000501777A (ja) * 1997-02-19 2000-02-15 ミネソタ マイニング アンド マニュファクチャリング カンパニー メトキシ−パーフルオロプロパンの共沸組成物およびその使用
JP2004529314A (ja) * 2000-10-27 2004-09-24 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア プリオン株を決定する方法
JP2004050109A (ja) * 2002-07-23 2004-02-19 Matsushita Electric Ind Co Ltd 部品の洗浄方法及び洗浄装置
JP2004157124A (ja) * 2002-11-06 2004-06-03 F Hoffmann La Roche Ag アミロイド定量法
JP2004284996A (ja) * 2003-03-24 2004-10-14 Nicca Chemical Co Ltd 泡状アルコール組成物
JP2008535786A (ja) * 2005-02-28 2008-09-04 アルファベータ エイビー アミロイドベータ−ペプチドの凝集を低減する化合物
JP2007314767A (ja) * 2006-03-31 2007-12-06 Ethicon Inc 医療器具前処理用泡の配合組成
JP2013098303A (ja) * 2011-10-31 2013-05-20 Central Glass Co Ltd 洗浄乾燥剤およびそれを用いた基板の洗浄乾燥方法
JP2015511014A (ja) * 2012-03-13 2015-04-13 ヤンセン アルツハイマー イミュノセラピー アルツハイマー病の診断、予後および監視におけるオリゴマー型Ａβ
CN102879577A (zh) * 2012-11-01 2013-01-16 山东龙美生物医学科技有限公司 一种检测朊病毒的试剂盒及其制备方法
JP2019144220A (ja) * 2018-02-23 2019-08-29 学校法人麻布獣医学園 アミロイドタンパク質を抽出する試薬

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERLOSE JEAN-PHILIPPE, CONVERT ODILE, DEROSSI DANIELE, BRUNISSEN ALIE, CHASSAING GERARD: "Conformational and associative behaviours of the third helix of antennapedia homeodomain in membrane-mimetic environments", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 242, no. 2, 1 December 1996 (1996-12-01), pages 372 - 386, XP055821749 *
EJIMA, DAISUKE: "Brighten heavy-hearted protein refolding experiment? Topics", KAGAKU TO SEIBUTSU, vol. 35, no. 10, October 1997 (1997-10-01), pages 721 - 722 *
LONGWORTH, RUSKIN: "Fluoroketone, hydrates: ''Helix- breaking Solvents for Polypeptide and Proteins", NATURE, vol. 203, no. 4942, 18 July 1964 (1964-07-18), pages 295 - 296, XP008054062 *
VIEIRA, E. P. ET AL.: "Change and stabilization of the amyloid-beta(1-40) secondary structure by fluorocompounds", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1645, no. 1, 31 January 2003 (2003-01-31), pages 6 - 14, XP004401453, DOI: 10.1016/S1570-9639(02)00461-2 *
XUE CHRISTINE, LEE YOON KYUNG, TRAN JOYCE, CHANG DENNIS, GUO ZHEFENG: "A mix-and-click method to measure amyloid-beta concentration with sub-micromolar sensitivity", ROYAL SOCIETY OPEN SCIENCE, vol. 4, no. 8, 2017, pages 170325/1 - 170325/12, XP055821747 *

Similar Documents

Publication Publication Date Title
US11326131B2 (en) Cleaning composition
US7670549B2 (en) Multiple enzyme cleaner for surgical instruments and endoscopes
ES2544583T3 (es) Composición limpiadora desinfectante alcalina biodegradable con tensioactivo analizable
AU2008312365B2 (en) Prion deactivating composition and methods of using same
US8382912B2 (en) Biofilm-removing agent
WO2012090306A1 (fr) Procédé de nettoyage d'appareil médical
JP5584613B2 (ja) 医療器具の洗浄方法
JP6732454B2 (ja) 洗浄殺菌剤組成物
US10669513B2 (en) Compositions and methods for handling potential prion contamination
JP6324018B2 (ja) 血液分析器を洗浄するためのホルムアルデヒドを含まない洗浄剤組成物およびその使用法
JP2014012860A5 (fr)
WO2021090910A1 (fr) Agent d'altération de la structure moléculaire pour la détection d'agrégats protéiques, procédé de détection associé, agent de nettoyage d'équipement médical, agent de nettoyage du sol et procédé de nettoyage du sol
WO2021112172A1 (fr) Agent de nettoyage ainsi que procédé de nettoyage et dispositif de nettoyage utilisant un agent de nettoyage
JP3861166B2 (ja) 酵素含有洗浄剤組成物
RU2294756C1 (ru) Жидкое моющее средство "эверлюкс 63"
Hirata et al. Effects of surfactant and a hyperthermostable protease on infectivity of scrapie-infected mouse brain homogenate
JP2022056396A (ja) 洗浄剤、洗浄剤製品、及び物品の洗浄方法
EP1588721A1 (fr) composition pour désactiver prions infectant sur des surfaces, instruments et liquides contaminés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20883818

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20883818

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP